Sizzling Biotech Stocks Under Review – AMGN, ANAC, GILD, ARNA
Houston, TX – January 30, 2013 — (Net PR News) – AnotherWinningTrade.com, the leader for breaking information and up-to-date market activities on Wall Street, locates high-growth equity opportunities. To receive our FREE, comprehensive newsletter, visit AnotherWinningTrade.com.
Today’s focus is on: NASDAQ:AMGN, NASDAQ:ANAC, NASDAQ:GILD, NASDAQ:ARNA
Amgen, Inc. (NASDAQ:AMGN) percentage change increased 1.17%, to close at $86.59 with the total traded volume of 21.50 million shares, as compare to average volume of 5.30 million shares. The Company’s lowest price during last trade was $85.00 while its highest price remained 87.89 for the day.
AMGN’s total market capitalization is $65.46 billion, along with 756.00 million shares outstanding. Its beta value stands at 0.40 points and its earning per share remained $5.52.
Is AMGN A Solid Investment At These Levels? Find Out Exactly Where AMGN Is Headed With This TREND ANALYSIS REPORT
Amgen, Inc. (NASDAQ:AMGN) reported its results from the Phase 3 trial of Pegfilgrastim and Anti-VEGF Evaluation Study (PAVES).
Anacor Pharmaceuticals Inc (NASDAQ:ANAC) reported a plunge of -20.50%. After opening at the price of $4.00, its closing price for the day was $4.11.
Anacor Pharmaceuticals’ earning per share is $-1.92. The Company’s current market capitalization stands at $146.19 million, along with 35.57 million shares.
ANAC’s total trading volume for the day was 5.74 million shares, versus its average volume of 228,091.00 shares.
Get A Free Report And Detailed Analysis On ANAC CLICK HERE To Read
If we look at the previous 5 day’s performance of the stock, it remained decreasing with the drop of -17.64%. In its last one month’s trade, it plunged -19.09%.
Gilead Sciences, Inc. (NASDAQ:GILD) revealed that, on Monday, February 4, at 4:05 p.m. Eastern Time, it will release its financial results of fourth quarter and year end 2012. To discuss the financial result of the company and to provide a financial guidance for 2013 and general business update, it will host a conference call at 4:30 p.m. Eastern Time, on the same day.
Gilead Sciences, Inc. percentage change increased 1.17% to close at $39.90 with the total traded volume of 8.44million shares, as compared to average volume of 8.72 million shares. If we look at its previous three months trade, it gained 18.96%, while in the last 5 day’s it remained up 2.41%.
GILD’s shares were trading within the range of $39.29-$40.02, while its opening price was $39.34. Its market capitalization is $60.46 billion and EPS was $1.60.
How Should Investors React To GILD Now? Find Out In This TREND ANALYSIS REPORT
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) reported the decrease of -2.45% and closed at $8.35 with the total traded volume of 5.42 million shares. The stock’s opening price was $8.51.
The 52-week price range of the stock remained $1.66 – $13.50, while during last trade its minimum price was $8.31 and it gained its highest price of $8.55.
The company has a total of 217.29 million outstanding shares and its total market capitalization is $1.81 billion. The Company’s last 5 days shows a downtrend with a drop of -14.53%.
How Should Investors Trade ARNA Now? Don’t Trade ARNA Until You Read This TREND ANALYSIS REPORT
Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor’s reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. A third party has hired and paid IO News Wire twelve hundred and ninety five dollars for the publication and circulation of this news release. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. We have no ownership of equity, no representation; do no trading of any kind and send no faxes or emails.